AI Healthcare's Error Tolerance Problem Is Getting Personal

A Bluesky post circulating this week didn't argue that AI has no place in medicine. It argued something narrower and harder to dismiss: that a tool making consequential errors one time in five would end a human clinician's career, and we have decided, apparently without much public deliberation, that the same standard doesn't apply to software. That framing — not a rejection of AI but a demand for consistency — has become the sharpest instrument in a conversation that has grown louder than it's been in months.

The AI scribe market is where this argument is most concrete. "Heidi," a transcription product being actively marketed to physicians, has become a focal point not because anyone can point to a documented catastrophe, but because the promotional confidence feels untethered from clinical caution. A Bluesky thread noted the almost-too-perfect irony of a sales call about Heidi being dropped by a technical glitch — a minor embarrassment in most industries, a meaningful signal in one where infrastructure failures have different consequences. What's accumulating isn't evidence of disaster. It's a pattern of friction between how these tools are sold and how medicine actually works, and enough physicians are noticing that the friction is becoming the story.

Google quietly retired an AI feature that had been aggregating amateur medical advice, and the reaction was instructive. Nobody celebrated the decision as responsible product stewardship. The dominant read, in threads across Bluesky and in Hacker News comments, was that the feature should never have shipped — that the retirement confirmed a deployment-first, accountability-later logic that healthcare can't afford. When a company sunsets a consumer product, the worst case is embarrassment. When the same logic governs clinical tools, the worst case is different. Google's cleanup is being filed as exhibit A in a growing brief about who gets to decide when healthcare AI is ready, and whether "ready" is even a concept that current incentive structures can produce.

The political framing hardening around this beat is worth taking seriously. A Euronews piece on European AI healthcare regulation has been circulating with commentary that treats it less as a policy story and more as a mirror — a way of making visible, by contrast, what the American regulatory posture currently looks like. The phrase one Bluesky writer reached for was a billionaire with a chainsaw dismantling the institutional structures designed to make corporate error costly. That's not a technical argument. It's a claim that the accountability mechanisms healthcare AI would need to be safe are being stripped out at exactly the moment deployment is accelerating, and the timing is not a coincidence.

The communities that have the most at stake in all of this — the people in r/cancer and r/CancerFamilySupport working through diagnoses, caregiver exhaustion, and the specific terror of treatment decisions — are not part of this conversation. They're not asking about AI scribes or regulatory frameworks. They're asking whether their mother's oncologist will call back. The entire public debate about AI in healthcare is being conducted by people who are not, right now, patients, and that gap between the people building these systems and the people who will need them to work correctly is the thing the conversation keeps circling without landing on. Accountability arguments tend to get serious when the people asking them have skin in the game. Right now, they don't — and the industry is counting on that.